Hesperidin ameliorates behavioral impairments and neuropathology of transgenic APP/PS1 mice

Behavioural Brain Research

Volumn 281, Issue , 2015, Pages 32-42

  Li, Chaoyun ^a   Zug, Caroline ^a   Qu, Hongchun ^b   Schluesener, Hermann ^a   Zhang, Zhiyuan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CHONGQING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Alzheimer's disease; Behavioral deficit; Cerebral amyloidosis; Hesperidin; Neuro inflammation; Transgenic mouse model

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; HESPERIDIN; TRANSFORMING GROWTH FACTOR BETA; PRESENILIN 1;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; CELL ACTIVATION; CONTROLLED STUDY; DRUG STRUCTURE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NESTING; NEUROPATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; SOCIAL INTERACTION; TREATMENT DURATION; ANIMAL; BRAIN; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; PATHOLOGY; PLAQUE, AMYLOID; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; SOCIAL BEHAVIOR; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HESPERIDIN; MALE; MICE; MICE, TRANSGENIC; MICROGLIA; PLAQUE, AMYLOID; PRESENILIN-1; PSYCHOMOTOR PERFORMANCE; SOCIAL BEHAVIOR; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 84920876906     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.12.012     Document Type: Article

References (58)

1. Crespo M.E., Galvez J., Cruz T., Ocete M.A., Zarzuelo A. Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Med 1999, 65:651-653.
2. Tamilselvam K., Braidy N., Manivasagam T., Essa M.M., Prasad N.R., Karthikeyan S., et al. Neuroprotective effects of hesperidin, a plant flavanone, on rotenone-induced oxidative stress and apoptosis in a cellular model for Parkinson's disease. Oxid Med Cell Long 2013, 2013:102741.
3. Wilmsen P.K., Spada D.S., Salvador M. Antioxidant activity of the flavonoid hesperidin in chemical and biological systems. J Agric Food Chem 2005, 53:4757-4761.
4. Crozier A., Jaganath I.B., Clifford M.N. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 2009, 26:1001-1043.
5. Garg A., Garg S., Zaneveld L.J., Singla A.K. Chemistry and pharmacology of the Citrus bioflavonoid hesperidin. Phytother Res 2001, 15:655-669.
6. Menze E.T., Tadros M.G., Abdel-Tawab A.M., Khalifa A.E. Potential neuroprotective effects of hesperidin on 3-nitropropionic acid-induced neurotoxicity in rats. Neurotoxicology 2012, 33:1265-1275.
7. Fernandez M., Gobartt A.L., Balana M., Group C.S. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. BMC Neurol 2010, 10:87.
8. Lyketsos C.G., Steinberg M., Tschanz J.T., Norton M.C., Steffens D.C., Breitner J.C. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000, 157:708-714.
9. Margallo-Lana M., Swann A., O'Brien J., Fairbairn A., Reichelt K., Potkins D., et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001, 16:39-44.
10. Ballard C., Corbett A. Agitation and aggression in people with Alzheimer's disease. Curr Opin Psychiatry 2013, 26:252-259.
11. Herrmann N., Chau S.A., Kircanski I., Lanctot K.L. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 2011, 71:2031-2065.
12. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
13. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron 2002, 35:419-432.
14. Xu F., Grande A.M., Robinson J.K., Previti M.L., Vasek M., Davis J., et al. Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience 2007, 146:98-107.
15. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998, 4:97-100.
16. Liu L., Ikonen S., Heikkinen T., Tapiola T., van Groen T., Tanila H. The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice. Exp Neurol 2002, 173:196-204.
17. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006, 7:940-946.
18. Zhang Z.Y., Daniels R., Schluesener H.J. Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis. J Cell Mol Med 2013, 17:1566-1576.
19. Kalpana K.B., Devipriya N., Srinivasan M., Vishwanathan P., Thayalan K., Menon V.P. Evaluating the radioprotective effect of hesperidin in the liver of Swiss albino mice. Eur J Pharmacol 2011, 658:206-212.
20. Viswanatha G.L., Shylaja H., Sandeep Rao K.S., Santhosh Kumar V.R., Jagadeesh M. Hesperidin ameliorates immobilization-stress-induced behavioral and biochemical alterations and mitochondrial dysfunction in mice by modulating nitrergic pathway. ISRN Pharmacol 2012, 2012:479570.
21. Wesson D.W., Wilson D.A. Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav Brain Res 2011, 216:408-413.
22. Bolivar V.J., Walters S.R., Phoenix J.L. Assessing autism-like behavior in mice: variations in social interactions among inbred strains. Behav Brain Res 2007, 176:21-26.
23. Hibbits N., Pannu R., Wu T.J., Armstrong R.C. Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination. ASN Neuro 2009, 1.
24. de Chaumont F., Dallongeville S., Chenouard N., Herve N., Pop S., Provoost T., et al. Icy: an open bioimage informatics platform for extended reproducible research. Nat Methods 2012, 9:690-696.
25. Li Y.M., Li X.M., Li G.M., Du W.C., Zhang J., Li W.X., et al. In vivo pharmacokinetics of hesperidin are affected by treatment with glucosidase-like BglA protein isolated from yeasts. J Agric Food Chem 2008, 56:5550-5557.
26. Lee N.K., Choi S.H., Park S.H., Park E.K., Kim D.H. Antiallergic activity of hesperidin is activated by intestinal microflora. Pharmacology 2004, 71:174-180.
27. Wang Y.G. Extract inhibits endotoxin induced inflammatory protein activities in macrophages and microglias 2006, Chung Yuan Christian University.
28. Zhang Z.Y., Schluesener H.J. Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J Neuropathol Exp Neurol 2013, 72:178-185.
29. Youdim K.A., Dobbie M.S., Kuhnle G., Proteggente A.R., Abbott N.J., Rice-Evans C. Interaction between flavonoids and the blood-brain barrier: in vitro studies. J Neurochem 2003, 85:180-192.
30. Kumar P., Kumar A. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide. Behav Brain Res 2010, 206:38-46.
31. Chen S.F., Hsu C.W., Huang W.H., Wang J.Y. Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury. Br J Pharmacol 2008, 155:1279-1296.
32. Starkstein S.E., Jorge R., Mizrahi R., Robinson R.G. The construct of minor and major depression in Alzheimer's disease. Am J Psychiatry 2005, 162:2086-2093.
33. Spalletta G., Caltagirone C., Girardi P., Gianni W., Casini A.R., Palmer K. The role of persistent and incident major depression on rate of cognitive deterioration in newly diagnosed Alzheimer's disease patients. Psychiatry Res 2012, 198:263-268.
34. Torres-Lista V., Gimenez-Llort L. Impairment of nesting behaviour in 3xTg-AD mice. Behav Brain Res 2013, 247:153-157.
35. Zhang Z.Y., Li C., Zug C., Schluesener H.J. Icariin ameliorates neuropathological changes, TGF-beta1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis. PLoS ONE 2014, 9:e104616.
36. Filali M., Lalonde R., Rivest S. Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease. Genes Brain Behav 2009, 8:143-148.
37. Chung J.A., Cummings J.L. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurol Clin 2000, 18:829-846.
38. Frisoni G.B., Rozzini L., Gozzetti A., Binetti G., Zanetti O., Bianchetti A., et al. Behavioral syndromes in Alzheimer's disease: description and correlates. Dement Geriatr Cogn Disord 1999, 10:130-138.
39. Brown M.W., Aggleton J.P. Recognition memory: what are the roles of the perirhinal cortex and hippocampus. Nat Rev Neurosci 2001, 2:51-61.
40. Filali M., Lalonde R., Rivest S. Anomalies in social behaviors and exploratory activities in an APPswe/PS1 mouse model of Alzheimer's disease. Physiol Behav 2011, 104:880-885.
41. Kupershmidt L., Amit T., Bar-Am O., Youdim M.B., Weinreb O. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid Redox Signal 2012, 17:860-877.
42. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
43. Wang D.M., Li S.Q., Zhu X.Y., Wang Y., Wu W.L., Zhang X.J. Protective effects of hesperidin against amyloid-beta (Abeta) induced neurotoxicity through the voltage dependent anion channel 1 (VDAC1)-mediated mitochondrial apoptotic pathway in PC12 cells. Neurochem Res 2013, 38:1034-1044.
44. Emim J.A., Oliveira A.B., Lapa A.J. Pharmacological evaluation of the anti-inflammatory activity of a citrus bioflavonoid, hesperidin, and the isoflavonoids, duartin and claussequinone, in rats and mice. J Pharm Pharmacol 1994, 46:118-122.
45. Choi I.Y., Kim S.J., Jeong H.J., Park S.H., Song Y.S., Lee J.H., et al. Hesperidin inhibits expression of hypoxia inducible factor-1 alpha and inflammatory cytokine production from mast cells. Mol Cell Biochem 2007, 305:153-161.
46. Lippa C.F., Flanders K.C., Kim E.S., Croul S. TGF-beta receptors-I and -II immunoexpression in Alzheimer's disease: a comparison with aging and progressive supranuclear palsy. Neurobiol Aging 1998, 19:527-533.
47. Wyss-Coray T., Lin C., Yan F., Yu G.Q., Rohde M., McConlogue L., et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 2001, 7:612-618.
48. Gray C.W., Patel A.J. Regulation of beta-amyloid precursor protein isoform mRNAs by transforming growth factor-beta 1 and interleukin-1 beta in astrocytes. Brain Res Mol Brain Res 1993, 19:251-256.
49. Lesne S., Docagne F., Gabriel C., Liot G., Lahiri D.K., Buee L., et al. Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem 2003, 278:18408-18418.
50. Wyss-Coray T., Masliah E., Mallory M., McConlogue L., Johnson-Wood K., Lin C., et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 1997, 389:603-606.
51. Grammas P., Ovase R. Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain. Am J Pathol 2002, 160:1583-1587.
52. Wyss-Coray T., Lin C., Sanan D.A., Mucke L., Masliah E. Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol 2000, 156:139-150.
53. Tweedie D., Ferguson R.A., Fishman K., Frankola K.A., Van Praag H., Holloway H.W., et al. Tumor necrosis factor-alpha synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflamm 2012, 9:106.
54. Ghorbani A., Nazari M., Jeddi-Tehrani M., Zand H. The citrus flavonoid hesperidin induces p53 and inhibits NF-kappaB activation in order to trigger apoptosis in NALM-6 cells: involvement of PPARgamma-dependent mechanism. Eur J Nutr 2012, 51:39-46.
55. Paris D., Patel N., Quadros A., Linan M., Bakshi P., Ait-Ghezala G., et al. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett 2007, 415:11-16.
56. Wang D., Liu L., Zhu X., Wu W., Wang Y. Hesperidin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress in a mouse model of Alzheimer's disease. Cell Mol Neurobiol 2014, 34:1209-1221.
57. Sivilia S., Lorenzini L., Giuliani A., Gusciglio M., Fernandez M., Baldassarro V.A., et al. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. BMC Neurosci 2013, 14:44.
58. Su J., Gu J., Dong Z., Mei B. Ibuprofen rescues abnormalities in periodontal tissues in conditional presenilin 1 and presenilin 2 double knockout mice. Int J Mol Sci 2013, 14:18457-18469.